Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Compugen shares moved above their 200-day moving average, reaching $2.63 and last trading at $2.56 versus the $2.38 average.
• Analyst sentiment remains positive overall, with a consensus “Buy” rating and an average price target of $5.00, though one analyst downgraded the stock to “Hold” and Leerink Partners cut its target to $5.00 from $13.00.
• Compugen’s latest quarterly results exceeded expectations, reporting a loss of $0.07 per share versus the expected $0.08 loss and revenue of $2.60 million versus estimates of $1.28 million.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.38 and traded as high as $2.63. Compugen shares last traded at $2.56, with a volume of 192,801 shares.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings raised shares of Compugen from a "sell (d-)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Wall Street Zen cut shares of Compugen from a "buy" rating to a "hold" rating in a research note on Saturday, May 23rd. Leerink Partners reduced their price target on shares of Compugen from $13.00 to $5.00 and set an "outperform" rating for the company in a research report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Compugen in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $5.00.

Compugen Stock Down 1.2%

The company has a 50-day moving average of $2.44 and a 200 day moving average of $2.38. The stock has a market capitalization of $242.06 million, a PE ratio of 6.74 and a beta of 2.78.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%.The company had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million. During the same quarter last year, the firm posted ($0.08) EPS. As a group, equities analysts predict that Compugen Ltd. will post -0.27 EPS for the current fiscal year.

Institutional Trading of Compugen

Several large investors have recently bought and sold shares of the business. Bank Hapoalim BM purchased a new position in Compugen in the 4th quarter worth approximately $37,000. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Compugen in the fourth quarter valued at approximately $38,000. Calamos Advisors LLC purchased a new stake in shares of Compugen in the first quarter valued at approximately $63,000. Franklin Resources Inc. purchased a new stake in shares of Compugen in the second quarter valued at approximately $56,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of Compugen in the first quarter valued at approximately $68,000. Hedge funds and other institutional investors own 12.22% of the company's stock.

Compugen Company Profile

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.